Disease Markers / 2019 / Article / Tab 1

Research Article

Tumor Mutation Load: A Novel Independent Prognostic Factor in Stage IIIA-N2 Non-Small-Cell Lung Cancer

Table 1

Cox proportional hazards analysis for progression-free survival in stage IIIA-N2 NSCLC patients.

SxWaldOR (95% CI)

Gender (male, female)0.319660.3885850.8226261.4 (0.64-2.9)0.417
Age, yr (≤60, >60)-0.370590.496416-0.746540.69 (0.26-1.8)0.438
Smoking (Y, N)-0.837810.394112-2.125810.43 (0.2-0.94)0.031
KPS (>80, ≤80)-0.245170.388775-0.630620.78 (0.37-1.7)0.527
Largest tumor diameter (<3, 3-4.9, and ≥5)-0.027770.28055-0.0990.97 (0.56-1.7)0.921
Histology (adenocarcinoma, nonadenocarcinoma)0.155020.4703910.3295561.2 (0.46-2.9)0.738
pT status (T1-2, T3)-0.236630.543001-0.435790.79 (0.27-2.3)0.654
cN2 (Y, N)0.3566030.3806380.9370931.4 (0.68-3)0.350
Tumor differentiation (well differentiated, poorly differentiated)-0.579780.484415-1.196860.56 (0.22-1.4)0.253
Met mutation (Y, N)0.4316860.5076330.8503891.5 (0.57-4.2)0.415
Mutation -0.884980.397069-2.228780.41 (0.19-0.9)0.028
Mutation -0.788880.407384-1.936450.45 (0.2-1)0.045

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.